Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oramed PharmaceuticalsFRA:OJU1 -3.61%32 Dividend Payout Ratio is 2.92 as of Mar. 2026. GuruFocus rates FRA:OJU1 with a GF Score™ of 32/100. The stock has 4 warning signs investors should review. Among 134 Biotechnology companies, Oramed Pharmaceuticals ranks better than 85.82% on this metric.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Oramed Pharmaceuticals's Dividend Payout Ratio for the
months ended in Mar. 2026 was 2.92.
The historical rank and industry rank for Oramed Pharmaceuticals's Dividend Payout Ratio or its related term are showing as below:
FRA:OJU1'
s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.14
Current: 0.14
During the past 13 years, the highest Dividend Payout Ratio of Oramed Pharmaceuticals was 0.14. The lowest was 0.00. And the median was 0.00.
FRA:OJU1's Dividend Payout Ratio is ranked better than 85.82% of 134
companies
in the Biotechnology industry
Industry Median: 0.435
vs FRA:OJU1: 0.14
During the past 13 years, the highest Trailing Annual Dividend Yield of Oramed Pharmaceuticals was 6.07%. The lowest was 0.00%. And the median was 0.00%.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Oramed Pharmaceuticals (FRA:OJU1) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Oramed Pharmaceuticals Dividend Payout Ratio Related Terms
Oramed Pharmaceuticals Dividend Payout Ratio Historical Data
* Premium members only.
The historical data trend for Oramed Pharmaceuticals's Dividend Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oramed Pharmaceuticals Dividend Payout Ratio Chart
FRA:OJU1 vs CAMP, PYXS, ALEC: Dividend Payout Ratio Comparison
For the Biotechnology subindustry, Oramed Pharmaceuticals's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oramed Pharmaceuticals Dividend Payout Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Oramed Pharmaceuticals's Dividend Payout Ratio falls into.
Oramed Pharmaceuticals Dividend Payout Ratio Calculation
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
Oramed Pharmaceuticals's Dividend Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oramed Pharmaceuticals (FRA:OJU1) has a Dividend Payout Ratio of 2.92 as of Mar. 2026. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Oramed Pharmaceuticals and its competitors. According to the industry distribution chart, Oramed Pharmaceuticals ranks #19 out of 134 companies in the Biotechnology industry, placing it in the top 14.2%.
Is Oramed Pharmaceuticals' Dividend Payout Ratio too high?
Oramed Pharmaceuticals' current Dividend Payout Ratio is 2.92. The Biotechnology industry median Dividend Payout Ratio is 0.44. Oramed Pharmaceuticals' value of 2.92 is 571.3% above this industry median. Based on the distribution chart, Oramed Pharmaceuticals ranks #19 out of 134 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Oramed Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Oramed Pharmaceuticals' Dividend Payout Ratio compare to CAMP and PYXS?
According to the Biotechnology industry distribution chart, Oramed Pharmaceuticals ranks #19 out of 134 companies for Dividend Payout Ratio. This places Oramed Pharmaceuticals in the top 14% of its industry — outperforming the majority of peers. The industry median Dividend Payout Ratio is 0.44. Oramed Pharmaceuticals' value of 2.92 is 571.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Biotechnology company?
The median Dividend Payout Ratio among Biotechnology companies is 0.44, based on 134 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oramed Pharmaceuticals's current Dividend Payout Ratio of 2.92 is 571.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Oramed Pharmaceuticals and its competitors. For the Biotechnology industry, the median Dividend Payout Ratio is 0.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oramed Pharmaceuticals's current Dividend Payout Ratio is 2.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oramed Pharmaceuticals stock overvalued right now?
Oramed Pharmaceuticals (FRA:OJU1) has a current Dividend Payout Ratio of 2.92. The current Dividend Payout Ratio is 2.92 and 571.3% above the Biotechnology industry median of 0.44. Oramed Pharmaceuticals' overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Oramed Pharmaceuticals (FRA:OJU1), the current Dividend Payout Ratio is 2.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
32GF Score
Get the complete analysis for FRA:OJU1
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OJU1 has been successfully added to your 
